Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

1233 - cIAP-2 expression increases in elderly patients with squamous cell carcinoma of the head and neck


20 Dec 2015


Poster presentation 2


Ying-Wen Su


Annals of Oncology (2015) 26 (suppl_9): 93-102. 10.1093/annonc/mdv527


Y. Su1, C. Chen2, C. Chiang3, Y. Chang1, R. Hsieh1

Author affiliations

  • 1 Division Of Hematology And Medical Oncology, Department Of Internal Medicine, Mackay Memorial Hospital, 104 - Taipei/TW
  • 2 Department Of Pathology, Taipei Medical Unversity Hospital, Taipei/TW
  • 3 Good Clinical Research Center, Mackay Memorial Hospital, Taipei/TW


Abstract 1233


Recent study showed the response to induction of apoptosis and cell death varied by age. Over expression of cIAP-2, a member of inhibitor of apoptosis (IAP) protein family, has been found in tumors from squamous cell carcinoma of head and neck (SCCHN) but its correlation with age and survival in SCCHN has not been evaluated yet. Thus, we analyzed the expression of c-IAP2 and its impact on the survival of elderly patients with resected SCCHN.


Immunohistochemical (IHC) staining for cIAP-2 and other previously reported molecular markers were performed using tissue microarrays from 103 resected SCCHN patients. The expression was grouped according to IHC scores [negative (0), low expression (1, 2), and high expression (3)]. Statistical analysis was performed to determine the association of the association of cIAP-2 expression with clinical-pathological factors.


Thirty-three out of 103 studied patients (32.0%) were older than 60. High expression of cIAP-2 was observed in 14 (13.6%) cases. It was significantly higher in patients aged 60 or greater (age <60 vs. age > = 60, 1.4% vs. 15.2%, P = 0.012, Fisher's exact test). High expression of cIAP-2 and an age ≥60 were significantly associated with worse survival in univariate analysis (P = 0.02 and P = 0.03, respectively, log-rank test) but only an age ≥60, and not cIAP-2 expression, was prognostic in multivariate analysis (adjusted hazard ratio (HR) for age ≥60: 2.41, 95% confidence interval (CI): 1.17-4.97; HR for high expression of cIAP-2:0.93, 95% CI: 0.30-2.90).


High expression of cIAP-2 was found more frequently in elderly SCCHN patients but was not independently associated with survival after adjusting other clinical-pathologic factors.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings